In patients with HFrEF, sacubitril/valsartan reduced BP and the risk of death and HF hospitalizations; it may also help preserve kidney function.197–199 Modest decreases in triglycerides and increases in HDL-C and LDL-C have been reported.200 Sacubitril/valsartan may increase the risk of hypotension, hyperkalemia, and acute renal failure, and it should not be used with other RAS inhibitors, including ARBs, ACE inhibitors, or aliskiren. Here, ACE is linked to Hyperkalemia.